LifeMD Adds Foundayo Oral GLP-1 Pill at $149/Month for Weight Management
LifeMD now offers Foundayo, a once-daily oral GLP-1 therapy approved April 1, 2026, to eligible patients at $149 per month or as low as $25 with a savings card, with Medicare coverage expected July 2026. This marks the second oral GLP-1 weight management option, enhancing LifeMD’s telehealth care platform.
1. Launch of Foundayo in Weight Management Program
LifeMD has added Foundayo, an oral GLP-1 therapy approved April 1, 2026, to its weight management program, integrating with LillyDirect to fulfill prescriptions and ship directly to eligible patients.
2. Pricing and Insurance Coverage
Foundayo is priced at $149 per month for self-pay patients and as low as $25 with a Lilly savings card; Medicare coverage is expected to begin in July 2026, broadening access to older demographics.
3. Strategic Impact and Market Position
As the second oral GLP-1 therapy approved for weight management, Foundayo’s addition strengthens LifeMD’s portfolio alongside offerings from Novo Nordisk, reinforcing the company’s position as a leading telehealth destination for obesity care.